United Lab's UBT48128 Tablet for Overweight or Obesity Receives Implied Clinical Trial Approval in China

Stock News11-19 21:58

United Lab (03933) announced that the novel Class 1 drug UBT48128 Tablet, independently developed by its wholly-owned subsidiary United Biotechnology (Zhuhai Hengqin) Co., Ltd., has received implied approval from China's National Medical Products Administration for a new drug clinical trial for the overweight or obesity indication, with acceptance numbers CXHL2601252, CXHL2601253, and CXHL2601254.

UBT48128 Tablet is a small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist that works through multiple mechanisms, including promoting insulin secretion, controlling appetite, and regulating energy metabolism. Taken orally once daily, it can lower blood sugar and reduce body weight, helping to improve patient compliance.

Preclinical studies in multiple animal models show that UBT48128 can significantly reduce body weight, with weight-loss effects superior to the comparator formulations in the trials. The product is expected to demonstrate good therapeutic potential and provide a new treatment option for patients who are overweight or obese.

UBT48128 Tablet received new drug clinical trial approval from the U.S. Food and Drug Administration ("FDA") on August 11, 2026.

In the future, the company will continue to devote itself to the research and development of new products, with a focus on enhancing its competitiveness and creativity in the biopharmaceutical industry, and deepening its presence in the chronic disease treatment field. It aims to serve clinical needs and benefit patients with higher-quality products and a more comprehensive pipeline, which is expected to create greater returns for the company and its shareholders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment